



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/535,951	03/27/2000	Alan D. Schreiber	555-56	4293

7590 03/28/2002

Nixon & Vanderhye PC
1100 North Glebe Rd 8th Floor
Arlington, VA 22201-4714

EXAMINER

HUI, SAN MING R

ART UNIT	PAPER NUMBER
1617	

DATE MAILED: 03/28/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	09/535,951	SCHREIBER, ALAN D.
	Examiner San-ming Hui	Art Unit 1617

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 02 January 2002.
- 2a) This action is **FINAL**. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.
- 4) Claim(s) 8-13 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 8-13 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Disposition of Claims

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) The proposed drawing correction filed on _____ is: a) approved b) disapproved by the Examiner.
 If approved, corrected drawings are required in reply to this Office action.
- 12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
 * See the attached detailed Office action for a list of the certified copies not received.
- 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
 a) The translation of the foreign language provisional application has been received.
- 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413) Paper No(s). _____.
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) Notice of Informal Patent Application (PTO-152)
 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____. 6) Other: _____

DETAILED ACTION

The cancellation of claims 1-7 in amendment filed January 2, 2002 is acknowledged.

The addition of claims 8-13 in amendment filed January 2, 2002 is acknowledged.

The outstanding claim objection of claim 1 set forth in the previous office action is withdrawn in view of the cancellation of the claim.

Claims 8-13 are pending.

Claim Rejections – 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 8 and 9 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The phrase “progestational agent that has an effect on the sex organs of said mammal less than that of medroxyprogesterone” in claim 8, line 4 renders the claims indefinite. It is unclear what progestational agents are encompassed by the claim. Further, the nature of “effects” on the sex organs encompassed by the claims is unclear. Is the term “effect” herein referring to side effects? Is the “effect” referring to beneficial effects? Or does the term “effect” mean therapeutic effects? Does the term “effect” mean effects on the cellular level? Without knowing exactly what effects may

encompassed by the claim, one of ordinary skill in the art would not know what progestational agents are considered to be encompassed by the claims as being lesser in such effect than medroxyprogesterone.

New Ground of Rejection

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 8 and 9 are rejected under 35 U.S.C. 103(a) as being unpatentable over Aristoff et al. (WO90/15816) in view of Kuzuya et al. (J Cell Physiol, 1995; 164(3):658-667).

Aristoff et al. teaches a method of inhibiting angiogenesis disorders, broadly, including atherosclerosis using angiostatic steroid compounds, broadly, including 17-hydroxyprogesterone (see particular page 3, line 22 and page 7, line 30; claim 8).

Aristoff et al. does not expressly teach the use of 17-hydroxyprogesterone in a method to reduce atherosclerotic plaque.

Kuzuya et al. teaches that the development of atherosclerotic plaque is associated with neovascularization (angiogenesis) in the thickened intima and media of vascular walls (See the abstract). Kuzuya et al. also teaches that the progression of

atherosclerotic plaque may be contributed through the secretion of angiogenic factor by the smooth muscle cells (See particularly the abstract).

It would have been obvious for one of ordinary skill in the art at the time the invention was made to use 17-hydroxyprogesterone in a method to reduce atherosclerotic plaque.

One of ordinary skill in the art would have been motivated to use 17-hydroxyprogesterone in a method to reduce atherosclerotic plaque because any known angiostatic steroid compound including 17-hydroxyprogesterone, would have been reasonably expected to be useful in a method of inhibiting angiogenesis and reducing atherosclerotic plaque thereby since angiogenesis is known to be contributive factor in the progression of atherosclerotic plaque.

Claims 10-13 are rejected under 35 U.S.C. 103(a) as being unpatentable over Cincotta (US Patent 5,565,454) in view of de Gruijter et al. (Abstract of Metabolism, 1991; 40(11):1119-1121).

Cincotta et al. teaches a method of treating atherosclerosis using prolactin enhancer and/or prolactin inhibitors including haloperidol (see particular Col. 1, line 32 - Col.2, line 15; also Col.2, line 25 – 34; also Col.6, line 5-9). Cincotta et al. also teaches that prolactin enhancer could reduce the plasma triglyceride and cholesterol level (See col. 2, line 25-36). Cincotta et al. teaches that platelets and monocytes adhesion to the endothelium connective tissues may lead to restenosis (See col. 1, line 48 - col.2, line 15).

Cincotta et al. does not expressly teach the use of haloperidol specifically in a method of reducing atherosclerotic plaque.

de Gruijter et al. teaches Hypercholesterolemia or combined Hypercholesterolemia-hypertriglyceridemia could increase the adhesion of monocytes to the endothelium of the vessel wall that result in atherosclerotic plaque (See abstract).

It would have been obvious for one of ordinary skill in the art at the time the invention was made to use haloperidol in a method to reduce atherosclerotic plaque.

One of ordinary skill in the art would have been motivated to use haloperidol in a method to reduce atherosclerotic plaque because any known prolactin modulator compounds, including haloperidol, would have been reasonably expected to be useful in a method of reducing the platelets and monocytes adhesion to the endothelium or subendothelial connective tissue and reducing the plasma cholesterol and triglyceride level in patients. Elevated cholesterol and triglyceride level and increased adhesion of monocytes to the endothelium of blood vessel walls are known to increase the formation of atherosclerotic plaque. Therefore, reducing the plasma triglyceride and cholesterol level and adhesion of platelets and monocytes to the endothelium of blood vessel walls by a known prolactin enhancer such as haloperidol would have been reasonably expected to reduce atherosclerotic plaque based on the cited prior art, absent evidence to the contrary.

It is applicant's burden to demonstrate unexpected results over the prior art. See MPEP 716.02, also 716.02 (a) - (g). Furthermore, the unexpected results should be demonstrated with evidence that the differences in results are in fact unexpected and

unobvious and of both statistical and practical significance. *Ex parte Gelles*, 22 USPQ2d 1318, 1319 (Bd. Pat. App. & Inter. 1992). Moreover, evidence as to any unexpected benefits must be "clear and convincing" *In re Lohr*, 137 USPQ 548 (CCPA 1963), and be of a scope reasonably commensurate with the scope of the subject matter claimed, *In re Linder*, 173 USPQ 356 (CCPA 1972). In the instant case, example 1, which is the only example related to the claimed method of reducing atherosclerotic plaque load, in the specification has been considered but is not found persuasive because the example merely demonstrates the effectiveness of progesterone and haloperidol in the method of reducing atherosclerotic plaque. There is no comparative data resent. This is seen to be an expected effect based on the cited prior art. No convincing and clear unexpected result is seen.

Response to argument

Applicant's arguments with respect to claims 8-13 have been considered but are moot in view of the new ground(s) of rejection.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within

Art Unit: 1617

TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to San-ming Hui whose telephone number is (703) 305-1002. The examiner can normally be reached on Mon 9:00 to 1:00, Tu - Fri from 9:00 to 6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Minna Moezie, J.D., can be reached on (703) 308-4612. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4556 for regular communications and (703) 308-4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

Application/Control Number: 09/535,951
Art Unit: 1617

Page 8

San-ming Hui
March 25, 2002

Minna Moezie
MINNA MOEZIE, J.D.
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600